According to our latest study on “Brain Cancer Diagnostic Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Diagnostic Type, Cancer Type, End User, Tumor Size, and Geography,” the market is expected to reach US$ 7,378.57 million in 2028 from US$ 1,639.10 million in 2022; it is estimated to grow at a CAGR of 28.5.% during 2022–2028. The report highlights the key factors driving the brain cancer diagnostic market growth and prominent players with their developments in the brain cancer diagnostic market.
Get Sample Copy of this Report at https://www.theinsightpartners.com/sample/TIPRE00024461/
Some Leading Companies Analysis as Below- THERMO FISHER SCIENTIFIC INC; Siemens Healthineers AG; GE Healthcare; MDxHealth; NantOmics; Biocept, Inc.; Koninklijke Philips N.V.; Canon Medical Systems; Hitachi, Ltd.; Neusoft Medical Systems; KITZ HEIDELBERG; GENPATH; NVIDIA CORPORATION; ONCORA MEDICAL; BIOMIND; SOPHIA AND ONCODNA; Clinspec Diagnostics; Raindance Technologies, Inc; ROCHE DIAGNOSTICS; and Illumina, Inc are among the key players operating in the Brain Cancer Diagnostics market.
Brain cancers are caused due to extracellular growth of the cells in the brain that causes tumors. The tumor includes primary brain tumors and secondary brain tumors. Primary brain tumors are formed in the brain and do not spread to other body parts, whereas secondary tumors, also known as metastases, are those cancers that began in another part of the body. Brain tumors are categorized into 40 major types that are further classified into two major groups. Benign tumor is slow-growing and have less possibility to spread, and malignant tumor is cancerous and more likely to spread. The growth of the brain cancer diagnostics market is primarily attributed to the rising incidence of brain cancer and an increasing number of cigarette smokers worldwide. However, the high cost of brain tumor diagnosis restricts the market growth.
Check Exclusive Discount on this Report at https://www.theinsightpartners.com/discount/TIPRE00024461/
The global brain cancer diagnostic market, based on cancer type, is segmented into acoustic neuroma, astrocytomas, craniopharyngiomas, ganglioneuromas, glioblastoma multiforme, meningiomas, ependymomas, oligodendroglioma, low-grade tumors, and other brain cancer types. In 2021, the glioblastoma multiforme segment is likely to account the largest share of the market. Moreover, the same segment is expected to witness growth in its demand at the fastest CAGR from 2021 to 2028, owing to the rise in the incidence of glioblastoma multiforme globally. Glioblastoma Multiforme (GBM) is a fast-growing and aggressive brain tumor known as a grade IV astrocytoma. It penetrates surrounding brain tissue but does not usually spread to other organs. GBMs can develop spontaneously in the brain or from a lower-grade astrocytoma. GBM most commonly affects adults in the cerebral hemispheres, particularly the frontal and temporal lobes. GBM is a fatal brain cancer that can kill patients in six months or less if left untreated. It is critical to seek expert neuro-oncological and neurosurgical care as soon as possible, as this can affect overall survival. Sophisticated imaging techniques such as computed tomography (CT scan) and magnetic resonance imaging (MRI) can accurately pinpoint the location of brain tumors. Growing awareness about glioblastoma multiforme is driving the market growth.
Purchase this Report at https://www.theinsightpartners.com/buy/TIPRE00024461/
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi